Holding of core competence for precision medicine era
The paradigm of future medicine in the fourth industrial revolution era is shifting with personalized “precision medicine” at the center. Theragen Etex receives more attention because it has both gene analysis ability and personalized drug development capability, which are core technologies for “precision medicine.”

The world’s highest level of genome analysis technology
Theragen Etex has made excellent achievements using innovative technologies such as the creation of the world’s first female/tiger/minke whale genome maps and completion of the first domestic human genome map, holding the largest domestic genome analysis performance, and first commercialization of individual genome analysis service in Asia. The company is now poised to benefit from the new growth engine.

International GMP certified facilities, stable manufacturing and supply of medicines
Pharmaceutical Division increased production facilities, acquired GMP certification from international consultative group, Pharmaceutical Inspection Cooperation/Scheme (PIC/S), and now stably manufactures and supplies medicines with its distribution affiliated companies. It also actively conducts research for securing a new drug pipeline such as incrementally modified drugs (IMD) or orphan drugs.

Carcinogenic gene analysis and development of novel anticancer drug
With the cooperation of the world’s best research institutes and medical staff, we analyze variations in carcinogenic genes such as stomach cancer, liver cancer, head and neck cancers, and breast cancer and disease mechanisms. Vactosertib, a novel anticancer drug that we are developing, is under clinical trial in Korea and the US.

About Us
Group companies make efforts to achieve a healthier and happier tomorrow.

MedPacto, Inc. a subsidiary of Theragen Etex, a genome-based drug discovery and clinical-stage biotechnology company, announced today that it has entered into a clinical collaboration agreement with Merck & Co., Inc., Ke...

Identify the cause of recurrence of pediatric brain tumor using genetic analysis technique

Theragen Etex has developed a technique, which can identify the cause of recurrence of pediatric brain tumor, using genetic analysis technique.
A team, led by professors from Seoul National University Hospital an...

Genome Care, a subsidiary of Theragen Etex, said that it plans to launch two new inspection services that can increase the implantation rate of artificial insemination in infertile women.
The two services are end...

Theragen Etex has registered a patent regarding the use of big data technology in immunotherapy research.
This is the first time that a domestic biotech company obtained a patent in the field of providing biometr...

Medpacto presents its phase 1 clinical trial results on Vactosertib, an immunotherapy agent, during the upcoming 2018 American Society of Clinical Oncology next month.
Vactosertib is a drug candidate that selecti...